UNSPSC 51314349: Chlorpheniramine/phenylephrine/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314349 Chlorpheniramine/phenylephrine/phenyltoloxamine is a Commodity code that in recent state and local practice covers a broader pharmaceutical and over-the-counter product procurement category than the code name alone suggests. State and local governments soliciting under this code are buying generic multi-source pharmaceuticals, OTC products, and emergency response medications (notably naloxone) through both direct purchases and cooperative purchasing frameworks. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work spans fixed-price supply contracts with quarterly or ongoing delivery schedules, compliance with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and submission of detailed product specifications including National Drug Codes and packaging information. Vendors must maintain cGMP certification, demonstrate pricing flexibility across multiple net-price and WAC-based models, and carry substantial insurance including commercial general liability of up to $5 million per occurrence.

Geographic activity centers on Minnesota (through the Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon), Texas (via the Texas Health and Human Services Commission), and Florida (Seminole County). Recent opportunities include Seminole County's IFB60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline and July 1, 2026 contract start; and the Texas HHS Commission's RFI HHS0017013 posted April 3, 2026 exploring direct-to-manufacturer prescription programs. Most opportunities involve multi-year contracts with administrative fee requirements, mandatory use of authorized wholesalers, and detailed product-information submissions. Cooperative purchasing vehicles appear frequently, broadening geographic reach across multiple jurisdictions through single procurement processes.